University of Washington Positive Research
Welcome,         Profile    Billing    Logout  
 1 Trial 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Madero, Juan Sierra
STOMP, NCT05534984: Study of Tecovirimat for Human Mpox Virus

Active, not recruiting
3
719
Japan, US, RoW
Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label)
National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies
MPOX
10/24
09/25
EPCOvid-1, NCT04388410: Safety and Efficacy of Convalescent Plasma Transfusion for Patients With COVID-19

Recruiting
2b
410
RoW
convalescent plasma
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Hospital San Jose Tec de Monterrey, Instituto Nacional de Enfermedades Respiratorias, Instituto Nacional de Cardiologia Ignacio Chavez, Hospital General Dr. Manuel Gea González, Hospital Regional de Alta Especialidad del Bajio, Instituto Nacional de Cancerologia de Mexico
COVID-19
11/20
12/20
Ohmagari, Norio
STOMP, NCT05534984: Study of Tecovirimat for Human Mpox Virus

Active, not recruiting
3
719
Japan, US, RoW
Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label)
National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies
MPOX
10/24
09/25
Bender-Ignacio, Rachel
STOMP, NCT05534984: Study of Tecovirimat for Human Mpox Virus

Active, not recruiting
3
719
Japan, US, RoW
Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label)
National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies
MPOX
10/24
09/25
Madruga, Jose Valdez
STOMP, NCT05534984: Study of Tecovirimat for Human Mpox Virus

Active, not recruiting
3
719
Japan, US, RoW
Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label)
National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies
MPOX
10/24
09/25
PALISADE, NCT06134362: Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)

Recruiting
3
3500
RoW
CAB LA, Apretude, CAB LA for PrEP
ViiV Healthcare, GlaxoSmithKline, PPD DEVELOPMENT, LP
HIV Infections
06/28
06/28
B-Focus, NCT06497504: Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection

Recruiting
2
150
Europe, Canada, US, RoW
Bepirovirsen, Placebo
GlaxoSmithKline
Hepatitis B
01/27
05/27
Ghilardi, Fabio
STOMP, NCT05534984: Study of Tecovirimat for Human Mpox Virus

Active, not recruiting
3
719
Japan, US, RoW
Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label)
National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies
MPOX
10/24
09/25
Gallup, Lydia
NCT04983030: Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults

Active, not recruiting
1/2
36
US
Ad26.Mos4.HIV, MVA-BN-HIV, PGT121, PGDM1400, VRC07-523LS
Boris Juelg, MD PhD, Janssen Pharmaceuticals, Harvard School of Public Health (HSPH), National Institute of Allergy and Infectious Diseases (NIAID)
HIV, Acquired Immunodeficiency Syndrome, Immunologic Deficiency Syndrome, Acquired, Sexually Transmitted Diseases, Viral, Retroviridae Infections
02/26
04/26

Download Options